Evidence analysisOctober 30, 2026Evidence
PSUSA/00002893/202602

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Evidence Dossier: Periodic Safety Update Report Single Assessment on Tenoxicam (PSUSA/00002893/202602)
This dossier summarizes publicly available information from the European Medicines Agency (EMA) regarding the periodic safety update report single assessment (PSUSA) for tenoxicam, a non-steroidal anti-inflammatory drug (NSAID) authorized in the European Union. It focuses on the latest regulatory review published on October 30, 2026.
What is established
- Tenoxicam is an active pharmaceutical substance used in several medicinal products authorized within the EU primarily for managing inflammation and pain.
- The EMA regularly requires marketing authorization holders to submit Periodic Safety Update Reports (PSURs) on tenoxicam, which document ongoing pharmacovigilance data including adverse drug reactions and risk-benefit assessments.
- The latest PSUSA document with reference PSUSA/00002893/202602 reflects a consolidated safety evaluation of tenoxicam based on data collected since previous reports.
- The regulatory outcome stated for this PSUSA is “Maintenance,” indicating the medicine’s authorization status is upheld without changes in warnings, contraindications, or usage restrictions at this time.
- The EMA PSUSA process is a mandated pharmacovigilance activity aiming to ensure continued monitoring of medicinal products post-authorization in a standardized manner across EU member states.
What the source claims
- The EMA’s public communication states the PSUSA concerns assessment of the safety profile of tenoxicam based on reports submitted by the marketing authorization holder(s).
- The report analyses aggregated safety data including adverse events, serious adverse events, and other safety signals detected since prior assessments.
- The decision to maintain the product’s marketing authorization suggests no new major safety risks requiring regulatory action were identified during this reporting period.
- Document in the public domain includes lists of nationally authorized medicinal products containing tenoxicam and highlights continued authorisation status.
What may be missing from the usual framing
- The publicly available summary does not detail specific adverse events reported, their frequency, severity, or the methods used to assess causality between these events and tenoxicam.
- Information about potential underreporting of adverse effects, or limitations in the pharmacovigilance data collection, is not addressed in the summary.
- The PSUSA overview does not discuss any comparative safety evaluations with other NSAIDs or alternative treatment options.
- No elaboration on patient subgroups that may have differential risk profiles (elderly, comorbidities, concurrent medications) appears evident in the limited publicly accessible text.
- Potential commercial or regulatory incentives impacting the depth of data disclosure or interpretation by marketing authorization holders are not discussed.
Competing evidence or uncertainty
There is insufficient evidence from the public source to evaluate competing safety data or controversies arising around tenoxicam use. Independent studies or post-marketing surveillance reports external to the EMA submission might reveal additional information on safety concerns or usage patterns that are not captured here.
Specifically, limitations in pharmacovigilance systems, such as spontaneous reporting biases or inconsistent data quality across EU countries, could influence the comprehensiveness of the safety update report, but details on these factors are not provided.
Also, while the report outcome indicates maintenance of authorization, it does not confirm whether ongoing risk minimization measures or additional monitoring have been implemented in response to identified minor risks.
Why it matters
The PSUSA process is an important regulatory tool for transparency and continued monitoring of medicines post-market, helping health authorities and clinicians make informed decisions about drug safety.
For patients using tenoxicam, confirmation that the EMA has not raised new safety concerns can provide some reassurance about the medicine’s use under current guidelines. However, the absence of detailed safety data limits the capacity of independent observers, clinicians, and patients to fully assess risk-benefit aspects themselves.
Understanding the limitations and transparency in regulatory safety reporting highlights the ongoing need for comprehensive pharmacovigilance, including access to richer data, to improve public trust and clinical outcomes.
What to verify next
- Review the full text of the PSUSA report and associated documents on the EMA website to examine detailed safety data, adverse event summaries, and risk assessment methodologies.
- Consult independent pharmacovigilance studies or meta-analyses evaluating tenoxicam safety to cross-check EMA conclusions and identify any signals not captured by regulatory reports.
- Investigate any national regulatory communications or healthcare advisories related to tenoxicam issued after October 2026.
- Examine patient and clinical organizations’ perspectives on tenoxicam safety to complement regulatory findings.
- Assess the transparency practices of marketing authorization holders in reporting and responding to adverse drug reactions.
Note to readers: For a full understanding and up-to-date assessment, please consult the original EMA source document entitled “PSUSA/00002893/202602” and related regulatory information available through official channels.
Source & verification
Primary source: What's new · October 30, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…